Hudson Bay Capital Management
LEGN icon

Hudson Bay Capital Management’s Legend Biotech LEGN Stock Holding History

Hudson Bay Capital Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.72M Buy
+150,200
New +$2.86M 0.01% 682

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Hudson Bay Capital Management's LEGN Position: Q1 2026 in Review

Hudson Bay Capital Management increased its Legend Biotech (LEGN) stake by 52% in Q1 2026, buying an estimated $5.74M and bringing the position to 876,351 shares worth $15.9M. The position accounts for 0.05% of the portfolio, ranked #224.

Hudson Bay Capital Management first reported a position in LEGN in Q2 2020 and has held it in 18 quarters since. The position peaked at $122M in Q2 2020. 190 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Hudson Bay Capital Management held 876,351 shares of Legend Biotech worth $15.9M as of Q1 2026.
  • Hudson Bay Capital Management bought 301,351 Legend Biotech shares in Q1 2026, an estimated $5.74M.
  • Legend Biotech made up 0.05% of Hudson Bay Capital Management's portfolio in Q1 2026, its #224 holding.
  • Hudson Bay Capital Management first reported a position in Legend Biotech in Q2 2020 and has held it in 18 quarters since.
  • Hudson Bay Capital Management's Legend Biotech position peaked at $122M in Q2 2020.
  • 190 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.